These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 17140346

  • 1. Is there value in susceptibility testing of Pseudomonas aeruginosa causing chronic infection in patients with cystic fibrosis?
    Gilligan PH.
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):711-5. PubMed ID: 17140346
    [No Abstract] [Full Text] [Related]

  • 2. Routine susceptibility tests with ticarcillin and tobramycin in combination should be more appropriate than with each antibiotic alone in cystic fibrosis Pseudomonas aeruginosa.
    Lapointe JR, Bourget C, Mainville S, Lafleur L, Lagacé J, Montplaisir S.
    J Chemother; 1989 Jul; 1(4 Suppl):184-6. PubMed ID: 16312360
    [No Abstract] [Full Text] [Related]

  • 3. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis.
    Etherington C, Hall M, Conway S, Peckham D, Denton M.
    J Antimicrob Chemother; 2008 Feb; 61(2):425-7. PubMed ID: 18156280
    [Abstract] [Full Text] [Related]

  • 4. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?
    Macdonald D, Cuthbertson L, Doherty C, Campana S, Ravenni N, Taccetti G, Govan JR.
    J Antimicrob Chemother; 2010 Nov; 65(11):2373-5. PubMed ID: 20837573
    [Abstract] [Full Text] [Related]

  • 5. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
    Bosso JA, Mauldin PD, Steed LL.
    Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR, Pressler T, Høiby N.
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [Abstract] [Full Text] [Related]

  • 9. Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!
    Marshall BC.
    Am J Respir Crit Care Med; 2004 Apr 01; 169(7):781-2. PubMed ID: 15044219
    [No Abstract] [Full Text] [Related]

  • 10. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.
    Murray TS, Egan M, Kazmierczak BI.
    Curr Opin Pediatr; 2007 Feb 01; 19(1):83-8. PubMed ID: 17224667
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy.
    Wolter DJ, Acquazzino D, Goering RV, Sammut P, Khalaf N, Hanson ND.
    Clin Infect Dis; 2008 Jun 15; 46(12):e137-41. PubMed ID: 18462098
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Early infection and progression of cystic fibrosis lung disease.
    Koch C.
    Pediatr Pulmonol; 2002 Sep 15; 34(3):232-6. PubMed ID: 12203855
    [Abstract] [Full Text] [Related]

  • 17. Failure of local defense mechanisms in cystic fibrosis.
    Proesmans M, De Boeck K.
    Acta Otorhinolaryngol Belg; 2000 Sep 15; 54(3):367-72. PubMed ID: 11082773
    [Abstract] [Full Text] [Related]

  • 18. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis.
    Ferroni A, Guillemot D, Moumile K, Bernede C, Le Bourgeois M, Waernessyckle S, Descamps P, Sermet-Gaudelus I, Lenoir G, Berche P, Taddei F.
    Pediatr Pulmonol; 2009 Aug 15; 44(8):820-5. PubMed ID: 19598278
    [Abstract] [Full Text] [Related]

  • 19. Segregation and use of nonshared care settings reduce the risk of multiresistant P. aeruginosa infection. Re: Davies et al., "Multiresistant Pseudomonas aeruginosa in a pediatric cystic fibrosis center: natural history and implications for segregation," Pediatr Pulmonol 2003;35:253-256.
    Festini F, Ballarin S, Loganes C.
    Pediatr Pulmonol; 2003 Aug 15; 36(2):171; author reply 172. PubMed ID: 12833499
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.